The information set forth in Item 2.03 of this Current Report on Form8-K is incorporated herein by reference in this Item 1.01.

On June 30, 2017, ConforMIS,Inc. (the “Company”) entered into a Second Amendment (the “Amendment”) to the Loan and Security Agreement dated January 6, 2017 (as previously amended, the “Loan and Security Agreement”) with Oxford Finance LLC (“Oxford”).

The Amendment, among other things, amends the period during which ConforMIS was able to borrow the second term loan under the Loan and Security Agreement, and also amends the associated financial covenants of the Company. to the Loan and Security Agreement, the Company initially borrowed $15 million of capital, and two additional term loans of $15 million (the “Term B Loan”) and $20 million were to become available for specified periods, in each case, subject to the satisfaction of certain revenue milestones and customary drawdown conditions. The Amendment made the Term B Loan available to the Company through the earlier of (i) June 30, 2017, or (ii) an event of default under the Loan and Security Agreement.

Except as modified by the Amendment, all terms and conditions of the Loan and Security Agreement remain in full force and effect. A copy of the Amendment is attached hereto as Exhibit 10.1 and is incorporated herein by reference.

On June 30, 2017, the Company borrowed $15 million to the Term B Loan of the Loan and Security Agreement. The proceeds of the Term B Loan will be used to fund the Borrowers’ ongoing working capital needs.

(d)Exhibits.

ConforMIS Inc Exhibit
EX-10.1 2 conformisfullyexecutedse.htm EXHIBIT 10.1 conformisfullyexecutedse WEST277369211 368986-000133 SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS SECOND AMENDMENT to Loan and Security Agreement (this “Amendment”) is entered into as of June 30,…
To view the full exhibit click here

About ConforMIS,Inc. (NASDAQ:CFMS)

ConforMIS, Inc. is a medical technology company that uses its iFit Image-to-Implant technology platform to develop, manufacture and sell joint replacement implants. The Company’s products include iTotal CR, which is the cruciate-retaining, customized total knee replacement system to restore the natural shape of a patient’s knee; iTotal PS, which is the posterior cruciate ligament substituting, or posterior-stabilized, customized total knee replacement product to restore the natural shape of a patient’s knee; iDuo, which is the customized bicompartmental knee replacement system, and iUni, which is the customized unicompartmental knee replacement product for treatment of the medial or lateral compartment of the knee. Its iFit technology platform comprises three elements: iFit Design, iFit Printing and iFit Just-in-Time Delivery. The Company markets and sells its products in the United States, Germany, the United Kingdom, Austria, Ireland, Switzerland, Singapore and Hong Kong.